FREQUENCY OF AND TESTING PATTERNS FOR MICROSATELLITE INSTABILITY HIGH (MSI-H) AND DEFICIENT MISMATCH REPAIR (DMMR) AMONG SOLID TUMORS IN A US COMMUNITY ONCOLOGY SETTING

被引：0
|
作者：
Chase, M. [1 ]
Vasudevan, A. [2 ]
Amonkar, M.
Myer, N. [1 ]
Wang, T. [1 ]
Prabhu, V [3 ]
Turzhitsky, V [1 ]
Spira, A. [4 ]
机构：
[1] Merck Co Inc, Kenilworth, NJ USA
[2] Ontada, The Woodlands, TX USA
[3] Merck Co Inc, North Wales, PA USA
[4] US Oncol Res Virginia Canc Specialists, Faifax, VA USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EPH95
引用
下载
收藏
页码：S452 / S452
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of dostarlimab in UK-specific patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) or DNA polymerase epsilon, catalytic subunit (POLε)-mutated solid tumours in the GARNET study
    Samuel, L.
    Miller, R.
    Ross, P.
    Arkenau, T.
    Antony, G.
    Veneris, J.
    Rule, J.
    Starling, N.
    ANNALS OF ONCOLOGY, 2023, 34 : S73 - S74
  • [32] Pembrolizumab for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced endometrial cancer: Long-term follow-up results from KEYNOTE-158
    O'Malley, D.
    Bariani, G. M.
    Cassier, P. A.
    Marabelle, A.
    Hansen, A. R.
    De Jesus-Acosta, A.
    Miller, W. H.
    Safra, T.
    Italiano, A.
    Mileshkin, L.
    Yao, L.
    Gozman, A.
    Jin, F. J.
    Maio, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S796 - S797
  • [33] Real-life efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient (dMMR/ MSI-H) biliary tract cancer (BTC)
    le Brun, I. Campo
    Grapinet, E.
    Hollebecque, A.
    Aurillac, V.
    Parent, P.
    Girot, P.
    Gendreau, M.
    Rafert, S.
    Javed, S.
    Touchefeu, Y.
    Roth, G.
    Muller, M.
    Lequoy, M.
    Boileve, A.
    Decraecker, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S125 - S125
  • [34] Literature review and meta-analyses of the prevalence of microsatellite instability high (MSI-H) and deficient mismatch repair (dMMR) for colorectal (CRC), gastric (GC), endometrial (EC) and ovarian cancers (OC) in Chinese population
    Liu, Xiaoqiao
    Fan, Jiaqi
    Liaw, Kai-Li
    Xu, Mo
    Zhou, Yu
    Amonkar, Mayur
    Zeng, Gefei
    CANCER RESEARCH, 2019, 79 (13)
  • [35] Genomic landscapes to characterize mismatch-repair deficiency (dMMR)/microsatellite instability-high (MSI-H) gastrointestinal (GI) cancers stratified by tumor mutation burden (TMB)
    Wang, Jingyuan
    Xiu, Joanne
    Farrell, Alex Patrick
    Battaglin, Francesca
    Arai, Hiroyuki
    Millstein, Joshua
    Soni, Shivani
    Zhang, Wu
    Shields, Anthony F.
    Grothey, Axel
    Weinberg, Benjamin Adam
    Marshall, John
    Lou, Emil
    Khushman, Moh'd M.
    Sohal, Davendra
    Hall, Michael J.
    Oberley, Matthew James
    Spetzler, David
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [36] Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).
    Andre, Thierry
    Shiu, Kai-Keen
    Kim, Tae Won
    Jensen, Benny Vittrup
    Jensen, Lars Henrik
    Punt, Cornelis J. A.
    Smith, Denis Michel
    Garcia-Carbonero, Rocio
    Alcaide, Julia
    Gibbs, Peter
    De la Fouchardiere, Christelle
    Rivera, Fernando
    Elez, Elena
    Bendell, Johanna C.
    Le, Dung T.
    Yoshino, Takayuki
    Zhong, Wen Yan
    Fogelman, David R.
    Marinello, Patricia
    Diaz, Luis A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] Combination of nivolumab (nivo) 1 ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 Study
    Lonardi, S.
    Andre, T.
    Wong, K. Y. M.
    Morse, M.
    McDermott, R.
    Hill, A.
    Hendlisz, A.
    Lenz, H.
    Leach, J.
    Moss, R. A.
    Cao, Z. A.
    Ledeine, J.
    Kopetz, S.
    Overman, M.
    ANNALS OF ONCOLOGY, 2017, 28 : 3 - 3
  • [38] Experience of mismatch repair/microsatellite instability (MMR/MSI) testing among patients with advanced/metastatic colorectal cancer in the US
    Eriksson, Jennifer
    Amonkar, Mayur
    Al-Jassar, Gemma
    Lambert, Jeremy
    Malmenas, Mia
    Chase, Monica
    Sun, Lucy
    Kollmar, Linda
    Vichnin, Michelle
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (08) : 1355 - 1361
  • [39] Long-term follow-up of a phase II study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors
    Li, J.
    Xu, Y.
    Zang, A.
    Gao, Y.
    Gao, Q.
    Zhang, Y.
    Wang, D.
    Xu, J.
    Yuan, Y.
    Jiang, H.
    Ying, J.
    Shi, C.
    Deng, Y.
    Wang, J.
    Liu, T.
    Huang, Y.
    Shi, M.
    Wang, K.
    Hu, H.
    Shen, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S640 - S640
  • [40] Combination of nivolumab (nivo) plus ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.
    Andre, Thierry
    Lonardi, Sara
    Wong, Ka Yeung Mark
    Morse, Michael
    McDermott, Raymond S.
    Hill, Andrew Graham
    Hendlisz, Alain
    Lenz, Heinz-Josef
    Leach, Joseph W.
    Moss, Rebecca Anne
    Cao, Z. Alexander
    Ledeine, Jean-Marie
    Chan, Emily
    Kopetz, Scott
    Michael, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345